Pulmonary capillary leak syndrome following COVID‐19 virus infection

Bahloul, Mabrouk; Ketata, W.; Lahyeni, Dorra; Mayoufi, Houda; Kotti, A.; Smaoui, Fatma; Kallel, N.; Daoud, E.; Bouaziz, Mounir; Kammoun, S.

doi:10.1002/jmv.26152

Cited by 33 publications

(37 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, the use of vitamin C (dose: 3 g/day) in two patients with SARS-CoV-2 infection and pulmonary capillary leak syndrome and who had a good outcome was described in a case series study from Tunisia [ 26 ]. On the other hand, some other studies did not find any positive outcome associated with vitamin C administration.…”

Section: Resultsmentioning

confidence: 99%

Vitamin C in the Treatment of COVID-19

2021

View full text Add to dashboard Cite

Vitamin C is an essential nutrient that serves as antioxidant and plays a major role as co-factor and modulator of various pathways of the immune system. Its therapeutic effect during infections has been a matter of debate, with conflicting results in studies of respiratory infections and in critically ill patients. This comprehensive review aimed to summarize the current evidence regarding the use of vitamin C in the prevention or treatment of patients with SARS-CoV2 infection, based on available publications between January 2020 and February 2021. Overall, 21 publications were included in this review, consisting of case-reports and case-series, observational studies, and some clinical trials. In many of the publications, data were incomplete, and in most clinical trials the results are still pending. No studies regarding prevention of COVID-19 with vitamin C supplementation were found. Although some clinical observations reported improved medical condition of patients with COVID-19 treated with vitamin C, available data from controlled studies are scarce and inconclusive. Based on the theoretical background presented in this article, and some preliminary encouraging studies, the role of vitamin C in the treatment of patients with SARS-CoV-2 infection should be further investigated.

show abstract

Section: Resultsmentioning

confidence: 99%

Vitamin C in the Treatment of COVID-19

2021

View full text Add to dashboard Cite

show abstract

“…Pulmonary capillary leak in response to COVID-19 infection has also been reported ( Bahloul et al, 2020 ). Again, zinc status in the lung has been suggested to be important in the maintenance of capillary integrity further underscoring the importance of understanding the impact of alcohol on zinc utilization in lung ( Skalny et al, 2020 ).…”

Section: Auds and The Lungmentioning

confidence: 96%

Alcohol use disorder: A pre-existing condition for COVID-19?

Bailey

Samuelson

Wyatt

2021

Alcohol

View full text Add to dashboard Cite

Alcohol misuse is long established as a contributor to the pathophysiology of the lung. The intersection of multi-organ responses to alcohol-mediated tissue injury likely contributes to the modulation of lung in response to injury. Indeed, the negative impact of alcohol on susceptibility to infection and on lung barrier function is now well documented. Thus, the alcohol lung represents a very likely comorbidity for the negative consequences of both COVID-19 susceptibility and severity. In this review, we present the known alcohol misuse ramifications on the lung in the context of the current coronavirus pandemic.

show abstract

“…Dexamethasone may have benefit in ventilator induced lung injury [ 326 ]. There are case reports of the use of dexamethasone in the treatment of SARS-CoV-2 pneumonia complicated by pulmonary oedema resulting from the pulmonary capillary leak syndrome [ 327 ]. Preliminary non-peer reviewed data from the Randomised Evaluation of COVID-19 (RECOVERY) trial suggests a benefit in people with severe COVID-19 infection on ventilators in ICU (2020).…”

Section: Suggestions For Therapeutic Interventionmentioning

confidence: 99%

Preventing the development of severe COVID-19 by modifying immunothrombosis

Morris

Bortolasci

Puri³

et al. 2021

Life Sciences

View full text Add to dashboard Cite

Background COVID-19-associated acute respiratory distress syndrome (ARDS) is associated with significant morbidity and high levels of mortality. This paper describes the processes involved in the pathophysiology of COVID-19 from the initial infection and subsequent destruction of type II alveolar epithelial cells by SARS-CoV-2 and culminating in the development of ARDS. Main body The activation of alveolar cells and alveolar macrophages leads to the release of large quantities of proinflammatory cytokines and chemokines and their translocation into the pulmonary vasculature. The presence of these inflammatory mediators in the vascular compartment leads to the activation of vascular endothelial cells platelets and neutrophils and the subsequent formation of platelet neutrophil complexes. These complexes in concert with activated endothelial cells interact to create a state of immunothrombosis. The consequence of immunothrombosis include hypercoagulation, accelerating inflammation, fibrin deposition, migration of NET producing neutrophils into the alveolar apace, activation of the NLRP3 inflammazome, increased alveolar macrophage destruction and massive tissue damage by pyroptosis and necroptosis Therapeutic combinations aimed at ameliorating immunothrombosis and preventing the development of severe COVID19 are discussed in detail.

show abstract

Pulmonary capillary leak syndrome following COVID‐19 virus infection

Cited by 33 publications

References 6 publications

Vitamin C in the Treatment of COVID-19

Vitamin C in the Treatment of COVID-19

Alcohol use disorder: A pre-existing condition for COVID-19?

Preventing the development of severe COVID-19 by modifying immunothrombosis

Contact Info

Product

Resources

About